Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 1 Cancer Trials

District of Columbia

Phase 1 cancer trials in District of Columbia

36 Phase 1 cancer studies are recruiting participants at sites in 1 city across District of Columbia as of November 17, 2026, according to ClinicalTrials.gov.

Call (888) 927-9038
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Every District of Columbia city with a recruiting study

By research area: Lung Cancer (16), Breast Cancer (8), Lymphoma (6), Melanoma (3), Prostate Cancer (2), Pancreatic Cancer (1).

Washington D.C. (36).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Breast cancer: recently updated in District of Columbia

Basic details from each study's public record (the 12 most recently updated of 36). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pliant Therapeutics, Inc.
    Recruiting in
    Washington D.C.
    Registry record
    NCT06270706 · updated
  2. A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

    • Phase 1
    • Ages 18 to 55
    • Female participants
    Sponsor
    TerSera Therapeutics LLC
    Recruiting in
    Washington D.C.
    Registry record
    NCT07310420 · updated
  3. Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    ORIC Pharmaceuticals
    Recruiting in
    Washington D.C.
    Registry record
    NCT05315700 · updated
  4. A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    NiKang Therapeutics, Inc.
    Recruiting in
    Washington D.C.
    Registry record
    NCT07029399 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in District of Columbia on ClinicalTrials.gov.

Lung cancer: recently updated in District of Columbia

  1. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Institut de Recherches Internationales Servier
    Recruiting in
    Washington D.C.
    Registry record
    NCT05786924 · updated
  2. Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Washington D.C.
    Registry record
    NCT06287775 · updated
  3. A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Recruiting in
    Washington D.C.
    Registry record
    NCT07277413 · updated
  4. A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Recruiting in
    Washington D.C.
    Registry record
    NCT07111520 · updated
  5. Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Recruiting in
    Washington D.C.
    Registry record
    NCT04886804 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in District of Columbia on ClinicalTrials.gov.

Melanoma: recently updated in District of Columbia

  1. Blood-Brain Barrier Disruption Using Exablate Magnetic Resonance-Guided Low Intensity Focused Ultrasound With Microbubbles in Combination With T-Cell Infusion in Patients With Newly Diagnosed Diffuse Midline Glioma (LIFT)

    • Phase 1
    • Ages 3 to 25
    • All sexes
    Sponsor
    Children's National Research Institute
    Recruiting in
    Washington D.C.
    Registry record
    NCT07796061 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in District of Columbia on ClinicalTrials.gov.

Ask about studies in District of Columbia

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.

Phase 1 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-9038

or send a short form

How should we reach you?

Call